• Open-label extension of a 10-week double-blind study assessing the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination therapy in 2509 patients with Grade 2-3 hypertension.

• Patients received OLM/AML/HCTZ 20/5/12.5, 40/5/12.5, 40/5/25, 40/10/12.5 or 40/10/25 mg with up- or down-titration as needed to achieve blood pressure (BP) goal.

• At study end, significant reductions from baseline were observed in each treatment group for seated systolic blood pressure (SeSBP) (37-43 mmHg) and seated diastolic blood pressure (SeDBP) (22-27 mmHg); overall, 78.1% of patients achieved BP goal.

• OLM/AML/HCTZ triple combination therapy also led to a substantial reduction in the level of hypertension severity.

• Long-term treatment with OLM/AML/HCTZ triple combination therapy is effective and well tolerated in patients with Grade 2-3 hypertension.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Daiichi Sankyo Europe GmbH (Munich, Germany). Medical writing assistance for this study was provided by Phil Jones of inScience Communications, Springer Healthcare (Chester, UK). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).